Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to -$38.6 million.

  • Orchestra BioMed Holdings' Cash from Investing Activities fell 7027.11% to -$38.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.0 million, marking a year-over-year decrease of 125.97%. This contributed to the annual value of $13.1 million for FY2024, which is 22.48% up from last year.
  • Orchestra BioMed Holdings' Cash from Investing Activities amounted to -$38.6 million in Q3 2025, which was down 335.90% from $16.4 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Cash from Investing Activities high stood at $33.2 million for Q4 2023, and its period low was -$63.4 million during Q4 2022.
  • Over the past 3 years, Orchestra BioMed Holdings' median Cash from Investing Activities value was $8.1 million (recorded in 2023), while the average stood at $1.3 million.
  • Within the past 5 years, the most significant YoY rise in Orchestra BioMed Holdings' Cash from Investing Activities was 5,879.91% (2023), while the steepest drop was 92,514.89% (2023).
  • Quarterly analysis of 4 years shows Orchestra BioMed Holdings' Cash from Investing Activities stood at -$63.4 million in 2022, then soared by 152.31% to $33.2 million in 2023, then plummeted by 111.32% to -$3.8 million in 2024, then slumped by 7,027.11% to -$38.6 million in 2025.
  • Its Cash from Investing Activities stands at -$38.6 million for Q3 2025, versus $16.4 million for Q2 2025 and $13.0 million for Q1 2025.